EP4731244A1 - Analogue de glp-1 destiné à être utilisé dans le traitement de troubles métaboliques - Google Patents

Analogue de glp-1 destiné à être utilisé dans le traitement de troubles métaboliques

Info

Publication number
EP4731244A1
EP4731244A1 EP24734997.0A EP24734997A EP4731244A1 EP 4731244 A1 EP4731244 A1 EP 4731244A1 EP 24734997 A EP24734997 A EP 24734997A EP 4731244 A1 EP4731244 A1 EP 4731244A1
Authority
EP
European Patent Office
Prior art keywords
subject
pharmaceutical composition
dose
days
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24734997.0A
Other languages
German (de)
English (en)
Inventor
Rajamannar Thennati
Vinod Sampatrao BURADE
Muthukumaran Natarajan
Ravishankara Madavati NAGARAJA
Pradeep Shahi
Satishbhai Tribhovanbhai PANCHAL
Sudeep Kumar Agrawal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of EP4731244A1 publication Critical patent/EP4731244A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La divulgation concerne des méthodes d'utilisation d'un analogue de GLP-1 et d'une composition associée pour le traitement de troubles métaboliques, tels que l'obésité, le diabète, la stéatose hépatique associée à un dysfonctionnement métabolique (MASLD), la stéatohépatite associée à un dysfonctionnement métabolique (MASH) et l'hypertriglycéridémie. Plus spécifiquement, la divulgation concerne des méthodes de traitement de l'obésité chez un sujet, comprenant l'administration d'une quantité thérapeutiquement efficace de GL0034 au sujet. La divulgation concerne également des méthodes de traitement d'un trouble métabolique chez un sujet en ayant besoin, comprenant l'administration d'une quantité thérapeutiquement efficace de GL0034 au sujet. La divulgation concerne en outre des compositions comprenant du GL0034 pour le traitement de l'obésité, du diabète ou d'un autre trouble métabolique chez un sujet.
EP24734997.0A 2023-06-20 2024-06-06 Analogue de glp-1 destiné à être utilisé dans le traitement de troubles métaboliques Pending EP4731244A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202321042015 2023-06-20
IN202421015451 2024-03-01
PCT/IB2024/055560 WO2024261580A1 (fr) 2023-06-20 2024-06-06 Analogue de glp-1 destiné à être utilisé dans le traitement de troubles métaboliques

Publications (1)

Publication Number Publication Date
EP4731244A1 true EP4731244A1 (fr) 2026-04-29

Family

ID=91616485

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24734997.0A Pending EP4731244A1 (fr) 2023-06-20 2024-06-06 Analogue de glp-1 destiné à être utilisé dans le traitement de troubles métaboliques

Country Status (6)

Country Link
EP (1) EP4731244A1 (fr)
KR (1) KR20260022330A (fr)
CN (1) CN121368489A (fr)
AU (1) AU2024311368A1 (fr)
MX (1) MX2025015441A (fr)
WO (1) WO2024261580A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010505A (es) 2018-04-05 2021-01-15 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1.
WO2024148104A1 (fr) * 2023-01-03 2024-07-11 BioAge Labs, Inc. Polythérapie d'agoniste du récepteur d'apeline et d'agoniste du récepteur de glp-1 pour le traitement d'une maladie ou d'une affection associée à une prise de poids

Also Published As

Publication number Publication date
CN121368489A (zh) 2026-01-20
MX2025015441A (es) 2026-02-03
KR20260022330A (ko) 2026-02-19
AU2024311368A1 (en) 2026-01-15
WO2024261580A1 (fr) 2024-12-26

Similar Documents

Publication Publication Date Title
DO FREEMAN Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus
AU2019309796B2 (en) Methods of using a GIP/GLP1 co-agonist for therapy
Jacobsen et al. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics
JP3579048B2 (ja) ペプチドの使用
US20080213288A1 (en) Combined Use Of A Modulator Of CD3 And A GLP-1 Compound
Dharmalingam et al. Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus
CA2662622C (fr) Methodes d'administration d'agents hypoglycemiques a longue duree d'action
US20170319664A1 (en) Dosing regimen
EP1515749B1 (fr) Utilisation combinee d'un modulateur de cd3 et d'un compose a base de glp-1
Sisson Liraglutide: clinical pharmacology and considerations for therapy
US20230092769A1 (en) Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
EP4731244A1 (fr) Analogue de glp-1 destiné à être utilisé dans le traitement de troubles métaboliques
Pitocco et al. Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents
KR20110052990A (ko) 인슐린 글라르긴 및 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법
EP4090351B1 (fr) Schéma posologique de glp-1
US20210213104A1 (en) Glucagon and glp-1 co-agonists for the treatment of chronic kidney disease and diabetic kidney disease in type 2 diabetes
HK40094446A (zh) Glp-1给药方案
HK40083623A (en) Dosing regimen of glp-1
TW202529797A (zh) Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途
Robertson New developments in incretin‐based therapies: The current state of the field
Nicolucci et al. Liraglutide: A Review of its Use in the Treatment of Diabetes Mellitus

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR